View in EDS HTML Full Text PDF Full Text

SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study.

Saved in:
Bibliographic Details
Title: SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study.
Authors: Yang Y; Second Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Guo Y; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Zhu M; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Dong Z; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Jiang S; The Second People's Hospital of Hunan Province, Brain Hospital of Hunan Province, Hunan, China., Wen X; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China., Jiang Z; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. zhjiang@tmu.edu.cn.
Source: Discover oncology [Discov Oncol] 2026 May 05; Vol. 17 (1). Date of Electronic Publication: 2026 May 05.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101775142 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-6011 (Electronic) Linking ISSN: 27306011 NLM ISO Abbreviation: Discov Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42084806
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yang+Y%22">Yang Y</searchLink>; Second Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Guo+Y%22">Guo Y</searchLink>; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Zhu+M%22">Zhu M</searchLink>; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Dong+Z%22">Dong Z</searchLink>; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Jiang+S%22">Jiang S</searchLink>; The Second People's Hospital of Hunan Province, Brain Hospital of Hunan Province, Hunan, China.<br /><searchLink fieldCode="AU" term="%22Wen+X%22">Wen X</searchLink>; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Jiang+Z%22">Jiang Z</searchLink>; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, NationalClinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin' s ClinicalResearch Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China. zhjiang@tmu.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101775142%22">Discover oncology</searchLink> [Discov Oncol] 2026 May 05; Vol. 17 (1). <i>Date of Electronic Publication: </i>2026 May 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101775142 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2730-6011 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2227306011%22">27306011 </searchLink><i>NLM ISO Abbreviation: </i>Discov Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42084806
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12672-026-05110-0
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yang Y
      – PersonEntity:
          Name:
            NameFull: Guo Y
      – PersonEntity:
          Name:
            NameFull: Zhu M
      – PersonEntity:
          Name:
            NameFull: Dong Z
      – PersonEntity:
          Name:
            NameFull: Jiang S
      – PersonEntity:
          Name:
            NameFull: Wen X
      – PersonEntity:
          Name:
            NameFull: Jiang Z
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 05
              Text: 2026 May 05
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2730-6011
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Discover oncology
              Type: main
ResultId 1